BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37864244)

  • 1. Development of super-specific epigenome editing by targeted allele-specific DNA methylation.
    Rajaram N; Kouroukli AG; Bens S; Bashtrykov P; Jeltsch A
    Epigenetics Chromatin; 2023 Oct; 16(1):41. PubMed ID: 37864244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting oncogenic TERT promoter variants by allele-specific epigenome editing.
    Kouroukli AG; Rajaram N; Bashtrykov P; Kretzmer H; Siebert R; Jeltsch A; Bens S
    Clin Epigenetics; 2023 Nov; 15(1):183. PubMed ID: 37993930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allele-Specific Epigenome Editing.
    Bashtrykov P; Jeltsch A
    Methods Mol Biol; 2018; 1767():137-146. PubMed ID: 29524132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient Targeted DNA Methylation with dCas9-Coupled DNMT3A-DNMT3L Methyltransferase.
    Bashtrykov P; Rajaram N; Jeltsch A
    Methods Mol Biol; 2023; 2577():177-188. PubMed ID: 36173573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner.
    O'Geen H; Bates SL; Carter SS; Nisson KA; Halmai J; Fink KD; Rhie SK; Farnham PJ; Segal DJ
    Epigenetics Chromatin; 2019 May; 12(1):26. PubMed ID: 31053162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allele-specific genome targeting in the development of precision medicine.
    Wu J; Tang B; Tang Y
    Theranostics; 2020; 10(7):3118-3137. PubMed ID: 32194858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases.
    Lin L; Liu Y; Xu F; Huang J; Daugaard TF; Petersen TS; Hansen B; Ye L; Zhou Q; Fang F; Yang L; Li S; Fløe L; Jensen KT; Shrock E; Chen F; Yang H; Wang J; Liu X; Xu X; Bolund L; Nielsen AL; Luo Y
    Gigascience; 2018 Mar; 7(3):1-19. PubMed ID: 29635374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A.
    Huang YH; Su J; Lei Y; Brunetti L; Gundry MC; Zhang X; Jeong M; Li W; Goodell MA
    Genome Biol; 2017 Sep; 18(1):176. PubMed ID: 28923089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.
    Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE
    J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
    Lau CH; Suh Y
    Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
    Pflueger C; Tan D; Swain T; Nguyen T; Pflueger J; Nefzger C; Polo JM; Ford E; Lister R
    Genome Res; 2018 Aug; 28(8):1193-1206. PubMed ID: 29907613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editing of DNA Methylation Using dCas9-Peptide Repeat and scFv-TET1 Catalytic Domain Fusions.
    Morita S; Horii T; Hatada I
    Methods Mol Biol; 2018; 1767():419-428. PubMed ID: 29524149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allele-specific locus binding and genome editing by CRISPR at the p16INK4a locus.
    Fujita T; Yuno M; Fujii H
    Sci Rep; 2016 Jul; 6():30485. PubMed ID: 27465215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locus-Specific and Stable DNA Demethylation at the
    Albrecht C; Rajaram N; Broche J; Bashtrykov P; Jeltsch A
    Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38254969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
    Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
    Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted in vivo epigenome editing of H3K27me3.
    Fukushima HS; Takeda H; Nakamura R
    Epigenetics Chromatin; 2019 Mar; 12(1):17. PubMed ID: 30871638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing.
    Nuñez JK; Chen J; Pommier GC; Cogan JZ; Replogle JM; Adriaens C; Ramadoss GN; Shi Q; Hung KL; Samelson AJ; Pogson AN; Kim JYS; Chung A; Leonetti MD; Chang HY; Kampmann M; Bernstein BE; Hovestadt V; Gilbert LA; Weissman JS
    Cell; 2021 Apr; 184(9):2503-2519.e17. PubMed ID: 33838111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas mediated epigenome editing for cancer therapy.
    Ansari I; Chaturvedi A; Chitkara D; Singh S
    Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of aberrant imprinting by allele-specific epigenome editing.
    Bashtrykov P; Kungulovski G; Jeltsch A
    Clin Pharmacol Ther; 2016 May; 99(5):482-4. PubMed ID: 26537177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.